ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Androgen Society 3rd Annual Meeting Review (Day 1)
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 201333" data-attributes="member: 13851"><p><h2>Androgen Society 3rd Annual Meeting Review (Day 1) – Summary:</h2><p><strong><em>Abraham Morgentaler, MD, FACS, Associate Clinical Professor of Urologic Surgery at Harvard University, reviews the first day of the 3rd annual meeting of the Androgen Society, an international organization consisting of healthcare professionals interested in testosterone deficiency and its treatment.</em></strong> <em>Dr. Morgentaler notes that the day began with a presentation on the history of testosterone by Dr. Nieschlag, followed by a presentation by Drs. Ethan D. Grober and Michael S. Irwig on transgender men and the physical impact of testosterone. Dr. Morgentaler then reviews a panel discussion that covered the use of free testosterone, erythrocytosis management, and the role of testosterone therapy and PDE5 inhibitors in men with erectile dysfunction and low testosterone. He goes on to summarize presentations by Drs. E. David Crawford and Omer Raheem covered the use of androgen deprivation therapy (ADT) in local disease, biochemical failure, and advanced disease, as well as the sexual effects of testosterone. Dr. Crawford presented data showing that there is value in having a testosterone level below 20 nanograms per deciliter, and Dr. Raheem discussed a <a href="https://pubmed.ncbi.nlm.nih.gov/19996060/" target="_blank">study</a> that found that different forms of ADT should be used depending on patients’ cardiovascular issues. Dr. Morgentaler concludes by considering new testosterone formulations, including testosterone undecanoate, an oral soft gel, and injectables.</em></p><p><em></em></p><p><em>Summaries of days 2 and 3 of this conference will be posted on <strong>GRU</strong> in the coming weeks. For more on ADT, visit our <strong><a href="https://grandroundsinurology.com/next-generation-androgen-deprivation-therapy/" target="_blank">Next Generation Androgen Deprivation Therapy Learning Center</a></strong>.</em></p><p></p><p></p><p>[URL unfurl="true"]https://grandroundsinurology.com/androgen-society-3rd-annual-meeting-review-day-1/?utm_campaign=NGLC%20-%20ADT&utm_content=167383896&utm_medium=social&utm_source=twitter&hss_channel=tw-4825344058[/URL]</p><p></p><p></p><p></p><p></p><p></p><p>[ATTACH=full]14248[/ATTACH]</p><p>[ATTACH=full]14249[/ATTACH]</p><p>[ATTACH=full]14250[/ATTACH]</p><p>[ATTACH=full]14251[/ATTACH]</p></blockquote><p></p>
[QUOTE="madman, post: 201333, member: 13851"] [HEADING=1]Androgen Society 3rd Annual Meeting Review (Day 1) – Summary:[/HEADING] [B][I]Abraham Morgentaler, MD, FACS, Associate Clinical Professor of Urologic Surgery at Harvard University, reviews the first day of the 3rd annual meeting of the Androgen Society, an international organization consisting of healthcare professionals interested in testosterone deficiency and its treatment.[/I][/B] [I]Dr. Morgentaler notes that the day began with a presentation on the history of testosterone by Dr. Nieschlag, followed by a presentation by Drs. Ethan D. Grober and Michael S. Irwig on transgender men and the physical impact of testosterone. Dr. Morgentaler then reviews a panel discussion that covered the use of free testosterone, erythrocytosis management, and the role of testosterone therapy and PDE5 inhibitors in men with erectile dysfunction and low testosterone. He goes on to summarize presentations by Drs. E. David Crawford and Omer Raheem covered the use of androgen deprivation therapy (ADT) in local disease, biochemical failure, and advanced disease, as well as the sexual effects of testosterone. Dr. Crawford presented data showing that there is value in having a testosterone level below 20 nanograms per deciliter, and Dr. Raheem discussed a [URL='https://pubmed.ncbi.nlm.nih.gov/19996060/']study[/URL] that found that different forms of ADT should be used depending on patients’ cardiovascular issues. Dr. Morgentaler concludes by considering new testosterone formulations, including testosterone undecanoate, an oral soft gel, and injectables. Summaries of days 2 and 3 of this conference will be posted on [B]GRU[/B] in the coming weeks. For more on ADT, visit our [B][URL='https://grandroundsinurology.com/next-generation-androgen-deprivation-therapy/']Next Generation Androgen Deprivation Therapy Learning Center[/URL][/B].[/I] [URL unfurl="true"]https://grandroundsinurology.com/androgen-society-3rd-annual-meeting-review-day-1/?utm_campaign=NGLC%20-%20ADT&utm_content=167383896&utm_medium=social&utm_source=twitter&hss_channel=tw-4825344058[/URL] [ATTACH type="full" alt="Screenshot (4714).png"]14248[/ATTACH] [ATTACH type="full" alt="Screenshot (4715).png"]14249[/ATTACH] [ATTACH type="full" alt="Screenshot (4716).png"]14250[/ATTACH] [ATTACH type="full" alt="Screenshot (4717).png"]14251[/ATTACH] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Androgen Society 3rd Annual Meeting Review (Day 1)
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top